677 related articles for article (PubMed ID: 29443372)
21. Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
Máchal J; Hlinomaz O
Curr Vasc Pharmacol; 2019; 17(1):35-40. PubMed ID: 29412111
[TBL] [Abstract][Full Text] [Related]
22. Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study.
Deharo P; Quilici J; Bonnet G; Grosdidier C; Morange P; Alessi MC; Bonnet JL; Cuisset T
Platelets; 2016 Dec; 27(8):791-795. PubMed ID: 27275528
[TBL] [Abstract][Full Text] [Related]
23. Cell Surface Platelet Tissue Factor Expression: Regulation by P2Y
Brambilla M; Becchetti A; Rovati GE; Cosentino N; Conti M; Canzano P; Giesen PLA; Loffreda A; Bonomi A; Cattaneo M; De Candia E; Podda GM; Trabattoni D; Werba PJ; Campodonico J; Pinna C; Marenzi G; Tremoli E; Camera M
Arterioscler Thromb Vasc Biol; 2023 Oct; 43(10):2042-2057. PubMed ID: 37589138
[TBL] [Abstract][Full Text] [Related]
24. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.
Gargiulo G; Esposito G; Avvedimento M; Nagler M; Minuz P; Campo G; Gragnano F; Manavifar N; Piccolo R; Tebaldi M; Cirillo P; Hunziker L; Vranckx P; Leonardi S; Heg D; Windecker S; Valgimigli M
Circulation; 2020 Aug; 142(5):441-454. PubMed ID: 32795098
[TBL] [Abstract][Full Text] [Related]
25. Course of platelet miRNAs after cessation of P2Y12 antagonists.
Jäger B; Stojkovic S; Haller PM; Piackova E; Kahl BS; Andric T; Vargas KG; Wojta J; Huber K
Eur J Clin Invest; 2019 Aug; 49(8):e13149. PubMed ID: 31172515
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Immature Platelet Count to Established Predictors of Platelet Reactivity During Thienopyridine Therapy.
Stratz C; Bömicke T; Younas I; Kittel A; Amann M; Valina CM; Nührenberg T; Trenk D; Neumann FJ; Hochholzer W
J Am Coll Cardiol; 2016 Jul; 68(3):286-293. PubMed ID: 27417007
[TBL] [Abstract][Full Text] [Related]
27. Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.
Droppa M; Borst O; Rath D; Müller K; Gawaz M; Bhatt DL; Geisler T
Cell Physiol Biochem; 2017; 42(4):1336-1341. PubMed ID: 28700987
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamic effects during the transition between cangrelor and prasugrel.
Schneider DJ; Seecheran N; Raza SS; Keating FK; Gogo P
Coron Artery Dis; 2015 Jan; 26(1):42-8. PubMed ID: 25089928
[TBL] [Abstract][Full Text] [Related]
29. Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.
Mohammad MA; Andell P; Koul S; James S; Scherstén F; Götberg M; Erlinge D
Platelets; 2017 Jun; 28(4):414-416. PubMed ID: 27885888
[TBL] [Abstract][Full Text] [Related]
30. Current status of data on cangrelor.
Qamar A; Bhatt DL
Pharmacol Ther; 2016 Mar; 159():102-9. PubMed ID: 26802900
[TBL] [Abstract][Full Text] [Related]
31. Periprocedural platelet inhibition with cangrelor in P2Y
Droppa M; Spahn P; Takhgiriev K; Müller KAL; Alboji A; Straub A; Rath D; Jeong YH; Gawaz M; Geisler T
Int J Cardiol; 2016 Nov; 223():848-851. PubMed ID: 27580219
[TBL] [Abstract][Full Text] [Related]
32. Platelet Reactivity And Circulating Platelet-Derived Microvesicles Are Differently Affected By P2Y
Chyrchel B; Drożdż A; Długosz D; Stępień EŁ; Surdacki A
Int J Med Sci; 2019; 16(2):264-275. PubMed ID: 30745807
[No Abstract] [Full Text] [Related]
33. Translation of experimental cardioprotective capability of P2Y
Hjortbak MV; Olesen KKW; Seefeldt JM; Lassen TR; Jensen RV; Perkins A; Dodd M; Clayton T; Yellon D; Hausenloy DJ; Bøtker HE;
Basic Res Cardiol; 2021 May; 116(1):36. PubMed ID: 34037861
[TBL] [Abstract][Full Text] [Related]
34. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?
Alexopoulos D; Katogiannis K; Sfantou D; Lekakis J
Platelets; 2018 May; 29(3):228-237. PubMed ID: 29022423
[TBL] [Abstract][Full Text] [Related]
35. Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Tang XF; Fan JY; Meng J; Jin C; Yuan JQ; Yang YJ
Atherosclerosis; 2014 Apr; 233(2):568-578. PubMed ID: 24534451
[TBL] [Abstract][Full Text] [Related]
36. Cangrelor: A Review in Percutaneous Coronary Intervention.
Keating GM
Drugs; 2015 Aug; 75(12):1425-34. PubMed ID: 26201463
[TBL] [Abstract][Full Text] [Related]
37. Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies.
Armstrong PC; Hoefer T; Knowles RB; Tucker AT; Hayman MA; Ferreira PM; Chan MV; Warner TD
Arterioscler Thromb Vasc Biol; 2017 May; 37(5):949-956. PubMed ID: 28279968
[TBL] [Abstract][Full Text] [Related]
38. Emerging P2Y12 receptor antagonists: role in coronary artery disease.
Oliphant CS; Doby JB; Blade CL; Das K; Mukherjee D; Das P
Curr Vasc Pharmacol; 2010 Jan; 8(1):93-101. PubMed ID: 19485932
[TBL] [Abstract][Full Text] [Related]
39. Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients.
Capodanno D; Angiolillo DJ
Expert Rev Cardiovasc Ther; 2016 Jul; 14(7):811-20. PubMed ID: 26953527
[TBL] [Abstract][Full Text] [Related]
40. Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes.
Wadowski PP; Weikert C; Pultar J; Lee S; Eichelberger B; Koppensteiner R; Lang IM; Panzer S; Gremmel T
Cardiovasc Drugs Ther; 2020 Feb; 34(1):53-63. PubMed ID: 32062795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
